• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Annexin Pharmaceuticals

13.00 SEK

0.00 %

Less than 1K followers

ANNX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
-13.04 %
-10.34 %
-34.34 %
-42.98 %
-62.54 %
-77.44 %
-86.34 %
-95.93 %

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Read more
Market cap
91.77M SEK
Turnover
219.61K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
16/7
2026

Interim report Q2'26

22/10
2026

Interim report Q3'26

11/2
2027

Annual report '26

Press release6/5/2026, 6:30 AM

Annexin Pharmaceuticals presenterar på Aktiedagarna i Stockholm den 10 juni

Annexin Pharmaceuticals
Press release6/5/2026, 6:30 AM

Annexin Pharmaceuticals to present at Aktiedagarna in Stockholm on June 10

Annexin Pharmaceuticals
Regulatory press release6/3/2026, 8:50 PM

Annexin genomför företrädesemission om cirka 20 MSEK, säkerställd till cirka 60 procent, med en övertilldelningsoption om upp till cirka 5 MSEK

Annexin Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/3/2026, 8:50 PM

Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million

Annexin Pharmaceuticals
Press release5/21/2026, 6:30 AM

Annexin utvärderar en tredagarsbehandling med ANXV för patienter med RVO

Annexin Pharmaceuticals
Press release5/21/2026, 6:30 AM

Annexin investigates a three-day ANXV treatment regimen in patients with RVO

Annexin Pharmaceuticals
Regulatory press release5/12/2026, 2:00 PM

Kommuniké från årsstämma i Annexin Pharmaceuticals AB

Annexin Pharmaceuticals
Press release5/11/2026, 6:30 AM

Annexin får kliniskt prövningsgodkännande i Tyskland – breddar patientrekryteringen i NEXUS-studien

Annexin Pharmaceuticals
Press release5/11/2026, 6:30 AM

Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study

Annexin Pharmaceuticals
Press release4/24/2026, 7:40 AM

Redeye: Annexin Pharmaceuticals (Q1 review): Study on track

Annexin Pharmaceuticals
Regulatory press release4/23/2026, 6:30 AM

Annexin Pharmaceuticals delårsrapport januari - mars 2026

Annexin Pharmaceuticals
Press release4/22/2026, 6:30 AM

Annexin accelererar patientrekrytering– fem patienter behandlade

Annexin Pharmaceuticals
Press release4/22/2026, 6:30 AM

Annexin accelerates patient recruitment – five patients treated

Annexin Pharmaceuticals
Regulatory press release4/13/2026, 11:29 AM

Annexin säkrar finansiering genom brygglånefacilitet och planerar företrädesemission om cirka 20 MSEK under sommaren 2026

Annexin Pharmaceuticals
Regulatory press release4/13/2026, 11:29 AM

Annexin secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026

Annexin Pharmaceuticals
Regulatory press release4/9/2026, 6:30 AM

KALLELSE TILL ÅRSSTÄMMA I ANNEXIN PHARMACEUTICALS AB (PUBL)

Annexin Pharmaceuticals
Regulatory press release3/26/2026, 7:30 AM

Annexin Pharmaceuticals publicerar årsredovisningen för 2025

Annexin Pharmaceuticals
Press release2/6/2026, 2:17 PM

Redeye: Annexin Pharmaceuticals (Q4 review): Phase II study away, with positive initial results

Annexin Pharmaceuticals
Regulatory press release2/5/2026, 7:30 AM

Annexin Pharmaceuticals bokslutskommuniké 2025

Annexin Pharmaceuticals
Regulatory press release2/4/2026, 1:36 PM

Gynnsamma resultat i Annexins pågående fas 2a-studie inom diabetesretinopati och retinal venocklusion

Annexin Pharmaceuticals